Revision as of 11:22, 13 May 2024

Back to Top

The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. Is there a regimen missing from this list? See the main HCC page for current regimens.

4 regimens on this page 7 variants on this page

First-line therapy for advanced or metastatic disease

Capecitabine monotherapy

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Abdel-Rahman et al. 2013	2010-2011	Randomized Phase 2 (E-switch-ooc)	Sorafenib	Inferior PFS (primary endpoint)

Note: Neither the primary outcome (progression-free survival) or secondary outcome (overall survival) were met.

Chemotherapy

Capecitabine (Xeloda) 1000 mg/m² PO twice per day on days 1 to 14

21-day cycles

References

Retrospective: Patt YZ, Hassan MM, Aguayo A, Nooka AK, Lozano RD, Curley SA, Vauthey JN, Ellis LM, Schnirer II, Wolff RA, Charnsangavej C, Brown TD. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer. 2004 Aug 1;101(3):578-86. link to original article PubMed
Abdel-Rahman O, Abdel-Wahab M, Shaker M, Abdel-Wahab S, Elbassiony M, Ellithy M. Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma. Med Oncol. 2013 Sep;30(3):655. Epub 2013 Jul 4. link to original article PubMed

Nivolumab monotherapy

Regimen variant #1, weight-based

Study	Dates of enrollment	Evidence	Efficacy
El-Khoueiry et al. 2017 (CheckMate 040)	2012-2016	Phase 1/2 (RT)	ORR: 20% (95% CI, 15–26)

Note: This is the dose used in the expansion cohort of this study; patients were required to have ECOG PS 1 or less, and Child-Pugh scores of 6 or less (Child-Pugh A) for the dose expansion. 68% of patients in the dose expansion phase received prior sorafenib therapy.

Immunotherapy

Nivolumab (Opdivo) 3 mg/kg IV once on day 1

14-day cycles

Regimen variant #2, flat dosing

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Yau et al. 2021 (CheckMate 459)	2016-01-11 to 2017-05-24	Phase 3 (E-switch-ooc)	Sorafenib	Might have superior OS (primary endpoint) Median OS: 16.4 vs 14.7 mo (HR 0.85, 95% CI 0.72-1.02)

Note: Study included patients with Child-Pugh class B (5-9), hepatitis B and C infections. This study was the basis for the withdrawal of FDA approval for this indication.

Immunotherapy

Nivolumab (Opdivo) 240 mg IV once on day 1

14-day cycles

References

CheckMate 040: El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH 3rd, Meyer T, Kang YK, Yeo W, Chopra A, Anderson J, Dela Cruz C, Lang L, Neely J, Tang H, Dastani HB, Melero I. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017 Jun 24;389(10088):2492-2502. Epub 2017 Apr 20 link to original article contains dosing details in abstract PubMed NCT01658878
1. Update: El-Khoueiry AB, Trojan J, Meyer T, Yau T, Melero I, Kudo M, Hsu C, Kim TY, Choo SP, Kang YK, Yeo W, Chopra A, Soleymani S, Yao J, Neely J, Tschaika M, Welling TH, Sangro B. Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040. Ann Oncol. 2023 Dec 25:S0923-7534(23)05115-3. Epub ahead of print. link to original article PubMed
CheckMate 459: Yau T, Park JW, Finn RS, Cheng AL, Mathurin P, Edeline J, Kudo M, Harding JJ, Merle P, Rosmorduc O, Wyrwicz L, Schott E, Choo SP, Kelley RK, Sieghart W, Assenat E, Zaucha R, Furuse J, Abou-Alfa GK, El-Khoueiry AB, Melero I, Begic D, Chen G, Neely J, Wisniewski T, Tschaika M, Sangro B. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022 Jan;23(1):77-90. Epub 2021 Dec 13. link to original article contains dosing details in abstract PubMed NCT02576509

Sunitinib monotherapy

Regimen variant #1, interrupted sunitinib

Study	Dates of enrollment	Evidence
Zhu et al. 2009 (DF/HCC 05-348)	2006-NR	Phase 2

Targeted therapy

Sunitinib (Sutent) 37.5 mg PO once per day on days 1 to 28

42-day cycles

Regimen variant #2, continuous sunitinib

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Cheng et al. 2013 (SUN 1170)	2008-2010	Phase 3 (E-switch-ic)	Sorafenib	Inferior OS (primary endpoint) Median OS: 7.9 vs 10.2 mo (HR 1.30, 95% CI 1.13-1.50)

Note: Early trial termination of SUN 1170 occurred for futility and safety reasons; sunitinib treated patients demonstrated inferior OS and more frequent and severe toxicities. Dosing preserved for historical context.

Targeted therapy

Sunitinib (Sutent) 37.5 mg PO once per day on days 1 to 28

28-day cycles

Dose and schedule modifications

Dose can be reduced to 25 and 12.5 mg once per day depending on toxicity

References

DF/HCC 05-348: Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, Sindhwani V, Blaszkowsky LS, Yoon SS, Lahdenranta J, Bhargava P, Meyerhardt J, Clark JW, Kwak EL, Hezel AF, Miksad R, Abrams TA, Enzinger PC, Fuchs CS, Ryan DP, Jain RK. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol. 2009 Jun 20;27(18):3027-35. Epub 2009 May 26. link to original article contains dosing details in manuscript link to PMC article PubMed NCT00361309
SUN 1170: Cheng AL, Kang YK, Lin DY, Park JW, Kudo M, Qin S, Chung HC, Song X, Xu J, Poggi G, Omata M, Pitman Lowenthal S, Lanzalone S, Yang L, Lechuga MJ, Raymond E. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol. 2013 Nov 10;31(32):4067-75. Epub 2013 Sep 30. link to original article PubMed NCT00699374

Tamoxifen monotherapy

Regimen variant #1, 20 mg/day

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Barbare et al. 2005 (FFCD 9403)	1995-2000	Phase 3 (E-esc)	Best supportive care	Did not meet primary endpoint of OS
Doffoël et al. 2008 (FFCD 9402)	1995-2002	Phase 3 (C)	TACE & Tamoxifen	Did not meet primary endpoint of OS
Verset et al. 2007	2001-2005	Phase 3 (C)	Octreotide LAR & Tamoxifen	Did not meet primary endpoint of OS

Endocrine therapy

Tamoxifen (Nolvadex) 20 mg PO once per day

Continued indefinitely

Regimen variant #2, 40 mg/day

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Gallo et al. 1998 (CLIP-1)	1995-1997	Phase 3 (E-esc)	Best supportive care	Did not meet primary endpoint of OS

Endocrine therapy

Tamoxifen (Nolvadex) 40 mg PO once per day

Continued indefinitely

References

CLIP-1: Gallo C, Daniele B, Gaeta GB, Perrone F, Pignata S; CLIP. Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. Lancet. 1998 Jul 4;352(9121):17-20. link to original article contains dosing details in abstract PubMed
FFCD 9403: Barbare JC, Bouché O, Bonnetain F, Raoul JL, Rougier P, Abergel A, Boige V, Denis B, Blanchi A, Pariente A, Milan C, Bedenne L. Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. J Clin Oncol. 2005 Jul 1;23(19):4338-46. link to original article contains dosing details in abstract PubMed
Verset G, Verslype C, Reynaert H, Borbath I, Langlet P, Vandebroek A, Peeters M, Houbiers G, Francque S, Arvanitakis M, Van Laethem JL. Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study. Br J Cancer. 2007 Sep 3;97(5):582-8. Epub 2007 Aug 7. link to original article link to PMC article contains dosing details in manuscript PubMed
FFCD 9402: Doffoël M, Bonnetain F, Bouché O, Vetter D, Abergel A, Fratté S, Grangé JD, Stremsdoerfer N, Blanchi A, Bronowicki JP, Caroli-Bosc FX, Causse X, Masskouri F, Rougier P, Bedenne L; Fédération Francophone de Cancérologie Digestive. Multicentre randomised phase III trial comparing Tamoxifen alone or with transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402). Eur J Cancer. 2008 Mar;44(4):528-38. Epub 2008 Jan 31. link to original article contains dosing details in manuscript PubMed

@@ Line 3: / Line 3: @@
 [[#top|Back to Top]]
 </div>
-The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the [http://www.nccn.org/professionals/physician_gls/f_guidelines.asp NCCN Guidelines]. Is there a regimen missing from this list? See the [[Hepatocellular_carcinoma|main HCC page]] for current regimens.
+The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. Is there a regimen missing from this list? See the [[Hepatocellular_carcinoma|main HCC page]] for current regimens.
 {| class="wikitable" style="float:right; margin-right: 5px;"
 |-
@@ Line 72: / Line 72: @@
 |[[Hepatocellular_carcinoma#Sorafenib_monotherapy|Sorafenib]]
 | style="background-color:#d9ef8b" |Might have superior OS (primary endpoint)<br>Median OS: 16.4 vs 14.7 mo<br>(HR 0.85, 95% CI 0.72-1.02)
+|-
 |}
 ''Note: Study included patients with Child-Pugh class B (5-9), hepatitis B and C infections. This study was the basis for the withdrawal of FDA approval for this indication.''
@@ Line 81: / Line 82: @@
 ===References===
 #'''CheckMate 040:''' El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH 3rd, Meyer T, Kang YK, Yeo W, Chopra A, Anderson J, Dela Cruz C, Lang L, Neely J, Tang H, Dastani HB, Melero I. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017 Jun 24;389(10088):2492-2502. Epub 2017 Apr 20 [https://doi.org/10.1016/S0140-6736(17)31046-2 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/28434648/ PubMed] [https://clinicaltrials.gov/study/NCT01658878 NCT01658878]
+##'''Update:''' El-Khoueiry AB, Trojan J, Meyer T, Yau T, Melero I, Kudo M, Hsu C, Kim TY, Choo SP, Kang YK, Yeo W, Chopra A, Soleymani S, Yao J, Neely J, Tschaika M, Welling TH, Sangro B. Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040. Ann Oncol. 2023 Dec 25:S0923-7534(23)05115-3. Epub ahead of print. [https://doi.org/10.1016/j.annonc.2023.12.008 link to original article] [https://pubmed.ncbi.nlm.nih.gov/38151184/ PubMed]
 <!-- #'''Abstract:''' Yau T, Park JW, Finn RS, Cheng A, Mathurin P, Edeline J, Kudo M, Han K, Harding JJ, Merle P, Rosmorduc O, Wyrwicz L, Schott E, Choo SP, Kelley RK, Begic D, Chen G, Neely J, Anderson J, Sangro B. CheckMate 459: A randomized, multi-center phase 3 study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Annals of Oncology. 2019 Sept; 30 (suppl_5): v851-v934. Epub 2019 Sept 27. [https://academic.oup.com/annonc/article/30/Supplement_5/mdz394.029/5577900 link to astract] -->
 #'''CheckMate 459:''' Yau T, Park JW, Finn RS, Cheng AL, Mathurin P, Edeline J, Kudo M, Harding JJ, Merle P, Rosmorduc O, Wyrwicz L, Schott E, Choo SP, Kelley RK, Sieghart W, Assenat E, Zaucha R, Furuse J, Abou-Alfa GK, El-Khoueiry AB, Melero I, Begic D, Chen G, Neely J, Wisniewski T, Tschaika M, Sangro B. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022 Jan;23(1):77-90. Epub 2021 Dec 13. [https://doi.org/10.1016/s1470-2045(21)00604-5 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/34914889/ PubMed] [https://clinicaltrials.gov/study/NCT02576509 NCT02576509]
 ==Sunitinib monotherapy {{#subobject:fc4f58|Regimen=1}}==
 <div class="toccolours" style="background-color:#ee6b6e">
-===Regimen {{#subobject:d4c1fd|Variant=1}}===
+===Regimen variant #1, interrupted sunitinib {{#subobject:d42zfd|Variant=1}}===
+{| class="wikitable sortable" style="width: 60%; text-align:center;"
+!style="width: 33%"|Study
+!style="width: 33%"|Dates of enrollment
+!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
+|-
+|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2702235/ Zhu et al. 2009 (DF/HCC 05-348)]
+|2006-NR
+| style="background-color:#91cf61" |Phase 2
+|-
+|}
+<div class="toccolours" style="background-color:#b3e2cd">
+====Targeted therapy====
+*[[Sunitinib (Sutent)]] 37.5 mg PO once per day on days 1 to 28
+'''42-day cycles'''
+</div></div><br>
+<div class="toccolours" style="background-color:#ee6b6e">
+===Regimen variant #2, continuous sunitinib {{#subobject:d4c1fd|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 !style="width: 20%"|Study
@@ Line 92: / Line 111: @@
 !style="width: 20%"|Comparator
 !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
-|-
-|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2702235/ Zhu et al. 2009 (DF/HCC 05-348)]
-|2006-NR
-| style="background-color:#91cf61" |Phase 2
-| style="background-color:#d3d3d3" |
-| style="background-color:#d3d3d3" |
 |-
 |[https://doi.org/10.1200/jco.2012.45.8372 Cheng et al. 2013 (SUN 1170)]
@@ Line 104: / Line 117: @@
 |[[Hepatocellular_carcinoma#Sorafenib_monotherapy|Sorafenib]]
 | style="background-color:#d73027" |Inferior OS (primary endpoint)<br>Median OS: 7.9 vs 10.2 mo<br>(HR 1.30, 95% CI 1.13-1.50)
+|-
 |}
-''Note: Early trial termination of the phase 3 trial occurred for futility and safety reasons; sunitinib treated patients demonstrated inferior OS and more frequent and severe toxicities. Dosing preserved for historical context.''
+''Note: Early trial termination of SUN 1170 occurred for futility and safety reasons; sunitinib treated patients demonstrated inferior OS and more frequent and severe toxicities. Dosing preserved for historical context.''
 <div class="toccolours" style="background-color:#b3e2cd">
 ====Targeted therapy====
 *[[Sunitinib (Sutent)]] 37.5 mg PO once per day on days 1 to 28
-'''42-day cycles'''
+'''28-day cycles'''
 </div>
 <div class="toccolours" style="background-color:#fff2ae">
 ====Dose and schedule modifications====
-**Dose can be reduced to 25 and 12.5 mg once per day depending on toxicity
+*Dose can be reduced to 25 and 12.5 mg once per day depending on toxicity
 </div></div>
 ===References===
 # '''DF/HCC 05-348:''' Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, Sindhwani V, Blaszkowsky LS, Yoon SS, Lahdenranta J, Bhargava P, Meyerhardt J, Clark JW, Kwak EL, Hezel AF, Miksad R, Abrams TA, Enzinger PC, Fuchs CS, Ryan DP, Jain RK. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol. 2009 Jun 20;27(18):3027-35. Epub 2009 May 26. [https://doi.org/10.1200/JCO.2008.20.9908 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2702235/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/19470923/ PubMed] [https://clinicaltrials.gov/study/NCT00361309 NCT00361309]
 # '''SUN 1170:''' Cheng AL, Kang YK, Lin DY, Park JW, Kudo M, Qin S, Chung HC, Song X, Xu J, Poggi G, Omata M, Pitman Lowenthal S, Lanzalone S, Yang L, Lechuga MJ, Raymond E. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol. 2013 Nov 10;31(32):4067-75. Epub 2013 Sep 30. [https://doi.org/10.1200/jco.2012.45.8372 link to original article] [https://pubmed.ncbi.nlm.nih.gov/24081937/ PubMed] [https://clinicaltrials.gov/study/NCT00699374 NCT00699374]
 ==Tamoxifen monotherapy {{#subobject:52e6cb|Regimen=1}}==
 <div class="toccolours" style="background-color:#ee6b6e">
-===Regimen {{#subobject:d856de|Variant=1}}===
+===Regimen variant #1, 20 mg/day {{#subobject:djg3ce|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 !style="width: 20%"|Study
@@ Line 127: / Line 142: @@
 !style="width: 20%"|Comparator
 !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
-|-
-|[https://doi.org/10.1016/S0140-6736(98)01259-8 Gallo et al. 1998 (CLIP-1)]
-|1995-1997
-| style="background-color:#1a9851" |Phase 3 (E-esc)
-|[[Hepatocellular_carcinoma_-_null_regimens#Best_supportive_care|Best supportive care]]
-| style="background-color:#ffffbf" |Did not meet primary endpoint of OS
 |-
 |[https://doi.org/10.1200/JCO.2005.05.470 Barbare et al. 2005 (FFCD 9403)]
@@ Line 145: / Line 154: @@
 |[[#TACE_.26_Tamoxifen_999|TACE & Tamoxifen]]
 | style="background-color:#ffffbf" |Did not meet primary endpoint of OS
-|-
-|[https://aasldpubs.onlinelibrary.wiley.com/doi/10.1053/jhep.2002.36824 Chow et al. 2002 (NMRC-AHCC01)]
-|1997-2000
-| style="background-color:#1a9851" |Phase 3 (E-esc)
-|[[Hepatocellular_carcinoma_-_null_regimens#Placebo_2|Placebo]]
-| style="background-color:#fc8d59" |Seems to have inferior OS
 |-
 |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360361/ Verset et al. 2007]
@@ Line 157: / Line 160: @@
 |[[#Octreotide_LAR_.26_Tamoxifen_999|Octreotide LAR & Tamoxifen]]
 | style="background-color:#ffffbf" |Did not meet primary endpoint of OS
+|-
+|}
+<div class="toccolours" style="background-color:#b3e2cd">
+====Endocrine therapy====
+*[[Tamoxifen (Nolvadex)]] 20 mg PO once per day
+'''Continued indefinitely'''
+</div></div><br>
+<div class="toccolours" style="background-color:#ee6b6e">
+===Regimen variant #2, 40 mg/day {{#subobject:d856de|Variant=1}}===
+{| class="wikitable sortable" style="width: 100%; text-align:center;"
+!style="width: 20%"|Study
+!style="width: 20%"|Dates of enrollment
+!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
+!style="width: 20%"|Comparator
+!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
+|-
+|[https://doi.org/10.1016/S0140-6736(98)01259-8 Gallo et al. 1998 (CLIP-1)]
+|1995-1997
+| style="background-color:#1a9851" |Phase 3 (E-esc)
+|[[Hepatocellular_carcinoma_-_null_regimens#Best_supportive_care|Best supportive care]]
+| style="background-color:#ffffbf" |Did not meet primary endpoint of OS
+|-
 |}
 <div class="toccolours" style="background-color:#b3e2cd">
 ====Endocrine therapy====
-*[[Tamoxifen (Nolvadex)]]
+*[[Tamoxifen (Nolvadex)]] 40 mg PO once per day
+'''Continued indefinitely'''
 </div></div>
 ===References===
-# '''CLIP-1:''' Gallo C, Daniele B, Gaeta GB, Perrone F, Pignata S; CLIP. Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. Lancet. 1998 Jul 4;352(9121):17-20. [https://doi.org/10.1016/S0140-6736(98)01259-8 link to original article] [https://pubmed.ncbi.nlm.nih.gov/9800740/ PubMed]
+# '''CLIP-1:''' Gallo C, Daniele B, Gaeta GB, Perrone F, Pignata S; CLIP. Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. Lancet. 1998 Jul 4;352(9121):17-20. [https://doi.org/10.1016/S0140-6736(98)01259-8 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/9800740/ PubMed]
-# '''NMRC-AHCC01:''' Chow PK, Tai BC, Tan CK, Machin D, Win KM, Johnson PJ, Soo KC; Asian-Pacific Hepatocellular Carcinoma Trials Group. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial. Hepatology. 2002 Nov;36(5):1221-6. [https://aasldpubs.onlinelibrary.wiley.com/doi/10.1053/jhep.2002.36824 link to original article] [https://pubmed.ncbi.nlm.nih.gov/12395333/ PubMed] [https://clinicaltrials.gov/study/NCT00003424 NCT00003424]
+# '''FFCD 9403:''' Barbare JC, Bouché O, Bonnetain F, Raoul JL, Rougier P, Abergel A, Boige V, Denis B, Blanchi A, Pariente A, Milan C, Bedenne L. Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. J Clin Oncol. 2005 Jul 1;23(19):4338-46. [https://doi.org/10.1200/JCO.2005.05.470 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/15994145/ PubMed]
-# '''FFCD 9403:''' Barbare JC, Bouché O, Bonnetain F, Raoul JL, Rougier P, Abergel A, Boige V, Denis B, Blanchi A, Pariente A, Milan C, Bedenne L. Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. J Clin Oncol. 2005 Jul 1;23(19):4338-46. [https://doi.org/10.1200/JCO.2005.05.470 link to original article] [https://pubmed.ncbi.nlm.nih.gov/15994145/ PubMed]
+# Verset G, Verslype C, Reynaert H, Borbath I, Langlet P, Vandebroek A, Peeters M, Houbiers G, Francque S, Arvanitakis M, Van Laethem JL. Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study. Br J Cancer. 2007 Sep 3;97(5):582-8. Epub 2007 Aug 7. [https://doi.org/10.1038/sj.bjc.6603901 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360361/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/17687341/ PubMed]
-# Verset G, Verslype C, Reynaert H, Borbath I, Langlet P, Vandebroek A, Peeters M, Houbiers G, Francque S, Arvanitakis M, Van Laethem JL. Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study. Br J Cancer. 2007 Sep 3;97(5):582-8. Epub 2007 Aug 7. [https://doi.org/10.1038/sj.bjc.6603901 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360361/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/17687341/ PubMed]
+# '''FFCD 9402:''' Doffoël M, Bonnetain F, Bouché O, Vetter D, Abergel A, Fratté S, Grangé JD, Stremsdoerfer N, Blanchi A, Bronowicki JP, Caroli-Bosc FX, Causse X, Masskouri F, Rougier P, Bedenne L; Fédération Francophone de Cancérologie Digestive. Multicentre randomised phase III trial comparing Tamoxifen alone or with transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402). Eur J Cancer. 2008 Mar;44(4):528-38. Epub 2008 Jan 31. [https://doi.org/10.1016/j.ejca.2008.01.004 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/18242076/ PubMed]
-# '''FFCD 9402:''' Doffoël M, Bonnetain F, Bouché O, Vetter D, Abergel A, Fratté S, Grangé JD, Stremsdoerfer N, Blanchi A, Bronowicki JP, Caroli-Bosc FX, Causse X, Masskouri F, Rougier P, Bedenne L; Fédération Francophone de Cancérologie Digestive. Multicentre randomised phase III trial comparing Tamoxifen alone or with transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402). Eur J Cancer. 2008 Mar;44(4):528-38. Epub 2008 Jan 31. [https://doi.org/10.1016/j.ejca.2008.01.004 link to original article] [https://pubmed.ncbi.nlm.nih.gov/18242076/ PubMed]
 [[Category:Hepatocellular carcinoma regimens]]
 [[Category:Historical regimens]]
 [[Category:Disease-specific pages]]
 [[Category:Hepatobiliary cancers]]

Difference between revisions of "Hepatocellular carcinoma - historical"

Revision as of 11:22, 13 May 2024

Contents

First-line therapy for advanced or metastatic disease

Capecitabine monotherapy

Regimen

Chemotherapy

References

Nivolumab monotherapy

Regimen variant #1, weight-based

Immunotherapy

Regimen variant #2, flat dosing

Immunotherapy

References

Sunitinib monotherapy

Regimen variant #1, interrupted sunitinib

Targeted therapy

Regimen variant #2, continuous sunitinib

Targeted therapy

Dose and schedule modifications

References

Tamoxifen monotherapy

Regimen variant #1, 20 mg/day

Endocrine therapy

Regimen variant #2, 40 mg/day

Endocrine therapy

References

Navigation menu

Search